

## LETTERS TO THE EDITOR

*To the Editor — The promising future of remote monitoring for cardiac implantable electronic devices.*

We read with interest the article by Heath and colleagues<sup>1</sup> in which they evaluated the performance of intensive remote monitoring (IRM) in comparison with standard remote monitoring for patients with a cardiac implantable electronic device. With the advancement of technology and its integration into healthcare, we congratulate the authors on this study and raising the awareness of this topic to the readership. The study found that using IRM led to a significant reduction in the number of actionable alerts and the time taken to review them. These results are important and may be relevant to other healthcare systems, for example the UK's National Health Service, in which remote monitoring is increasing,<sup>2</sup> although, as the authors discussed, the single-center nature of this study is a limitation and larger studies would be needed to generalize results beyond this area.

Although the methodology used was robust, they could have mentioned the method of data transmission utilized by patients in this study; for example, it is feasible that having a mobile transmitter, such as via a smartphone, as opposed to a stationary transmitter, perhaps by the patient's bedside, would result in different timings of transmissions. This could therefore impact the time from transmission to review. It could also be explored as to whether Internet connectivity had any impact on transmissions.

While the IRM and RM patient groups were similar in age, gender, body mass index, and indications for cardiac implantable electronic device, other factors such as comorbidities and activity levels were not mentioned. These could have been considered to better compare the groups and ensure that there was no significant difference between

them that could have affected the number of actionable alerts.

It is interesting that the total number of transmissions received from implantable cardioverter-defibrillators was decreased in the IRM group, but the total transmissions from permanent pacemaker and implantable loop recorder devices were increased compared with the RM group. We wonder whether the authors can advance any theory for why this might be, or whether it is attributable to random variation.

Philippa Whitaker\* (p.whitaker2@nhs.net),  
Idrees Latif, BSc\*, Vinod Patil, FRCA<sup>†</sup>

\*Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom; <sup>†</sup>Department of Anaesthesia, Barking Havering and Redbridge University Hospitals NHS Trust, Romford, United Kingdom

### Funding Sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### Disclosures

The authors have no conflicts to disclose.

### Authorship

All authors attest they meet the current ICMJE criteria for authorship.

### References

1. Heath K, O'Shea C, Thomas G, et al. Impact of intensive follow-up of cardiac implantable electronic devices via remote monitoring: a pilot study. *Heart Rhythm* 2022. XX:XXX-XXX.
2. Ahmed F, Sammut-Powell C, Martin GP, et al. Use of a device-based remote management heart failure care pathway is associated with reduced hospitalization and improved patient outcomes: TriageHF Plus real-world evaluation. *Eur Heart J* 2022;43:ehac544.2814.